46 results about "Heart contractility" patented technology

A device for treating cardiac disease of a heart includes a jacket of flexible material defining a volume between an open upper end and a lower end. The jacket is dimensioned for an apex of the heart to be inserted into the volume through the open upper end and for the jacket to be slipped over the heart. The jacket is adapted to be secured to the heart with the jacket having portions disposed on opposite sides of the heart. The jacket is adjustable to snugly conform to an external geometry of the heart and to constrain circumferential expansion of the heart during diastole and permit substantially unimpeded contraction of the heart during systole. A first and a second grid of electrodes are carried on the jacket. The grids are disposed to be in overlying relation to individual ones of the opposite sides of the heart when the jacket is secured to the heart. The first and second grids are connectable to a source of a defibrillating waveform.

The progression or regression of left ventricular dysfunction (LVD) is automatically evaluated by a pacemaker or other implantable cardiac stimulation device by tracking changes in the resting sinus rate of the patient in which the device is implanted. The resting sinus rate is detected by first determining whether the patient is in a state of profound rest, such as sleep, then measuring the actual sinus rate during profound rest. Profound rest may be detected by using an activity variance sensor. An increase in the profound rest sinus rate over a period of several months indicates progression of LVD; whereas a decrease indicates regression. Appropriate LVD diagnostic information is recorded for subsequent review by a physician. Based on the progression or regression of LVD, the physician may then modify LVD drug therapy administered to the patient or may adjust control parameters of the pacemaker, such as overdrive pacing control parameters or control parameters affecting heart contractility via post-extrasystolic potentiation. If a drug pump is implanted within the patient for automatically delivering LVD drug therapy, the pacemaker controls the drug pump in view of any detected progression or regression of LVD. The technique may also be used to verify the efficacy of LVD drug therapy administered to the patient, whether delivered via an implanted drug pump or otherwise. Processing may be primarily performed within the implanted device itself or with an external programmer in communication with the implanted device. Activity state-based LVD tracking techniques are also set forth.

A system for monitoring heart performance comprises a plurality of sensing devices configured to attach to a patient's heart tissue and a controller. Each sensing device comprises a sensor configured to detect physiological data relating to heart contractility and a wireless transmitter configured to transmit data detected by the sensor. The controller comprises a receiver configured to receive the detected data transmitted by the plurality of sensing devices and a processor configured to analyze the received data.

A method of placing and testing placement of a plurality of pacing and stimulation leads for cardiac resynchronization therapy (CRT) employs cardiac contractility modulation (CCM), using a plurality of cardiac contractility modulation leads placed at a plurality of sites.

A method is provided for trending heart failure based on heart contractility information comprises measuring cardiogenic impedance (CI) measurements along at least a first vector through a heart over a period of time. The method determines contractility estimates from the CI measurements, the contractility estimates relating to contractility of the heart. The method further obtains physiologic and/or surrogate signals representing estimates for or direct measurements of at least one of cardiac volume and pressure of the heart when the CI measurements were obtained. The method identifies correction factors based on the physiologic and/or surrogate signals and applies the correction factors to the contractility estimates to produce contractility trend values over the period of time. A system is provided for trending heart failure based on heart contractility information which comprises inputs to receive cardiogenic impedance (CI) measurements taken along at least a first vector through a heart over a period of time. The system includes a contractility module to determine contractility estimates from the CI measurements, the contractility estimates relating to contractility of the heart and a collection module to receive physiologic and/or surrogate signals representing estimates for or direct measurements of at least one of cardiac volume and pressure of the heart when the CI measurements were obtained. A factor module is also provided to identify correction factors based on the physiologic and/or surrogate signals and a correction module to apply the correction factors to the contractility estimates to produce contractility trend values over the period of time.

A Method for measuring heart contractility of a patient, in which a mechanical shear wave is propagated through the heart and observation of the propagation leads to determine a shear wave propagation parameter representative of the elasticity of the heart is disclosed. The value of the propagation parameter at the end of a systole is sampled, which leads to a parameter representative of the end systolic elastance.

The invention provides a treatment for congestive heart failure (CHF) in a patient. At least one pressure applicator is arranged externally around a body segment of the patient. Negative pressure, relative to atmospheric pressure, is applied to the body segment of the patient during cardiac systole using the pressure applicator, thereby reducing ventricular afterload in the patient. The negative pressure to the body segment of the patient is removed during cardiac diastole.

Methods and systems of treating acute heart failure by applying a therapy signal at least one sympathetic cardiopulmonary fiber surrounding the pulmonary trunk that affects heart contractility more than heart rate. Methods and systems also include adjusting the signal to effectuate treatment.

The invention relates to the technical field of medical instruments, in particular to an electromagnetic cardiac pulse assisting device. The electromagnetic cardiac pulse assisting device comprises an inner membrane, an outer membrane supporting body, two permanent magnets, electromagnets, a power source and a controller. The inner membrane covers the surface of the heart, and the outer membrane supporting body covers the outer side of the inner membrane. The two permanent magnets are fixed to the outer side of the inner membrane and correspond to the left ventricle and the right ventricle respectively. The two electromagnets are fixed to the inner side of the outer membrane supporting body and are opposite to the permanent magnets. The power source and the controller are used for supplying power to the electromagnets and adjusting the magnitude and the direction of current, so that the electromagnets can apply repulsive force or attractive force to the permanent magnets, and then the heart is driven to contract or relax. The device has the advantages of being capable of assisting the heart of the human body to beat, high in controllability, capable of improving the heart failure symptom and prolonging the service life of a patient, simple in structure, small and exquisite in size, capable of being implanted only through surgical operation, convenient to replace, low in manufacturing and using cost, long in service life and easy to accept by doctors and patients.

A cardiac stimulator having at least one stimulation unit which is connected or connectable to one or more stimulation electrodes, and is configured to deliver at least sub-threshold stimulation pulses for cardiac contraction modulation therapy, an impedance detection unit which is connectable to one or more electrodes, and is configured to detect a voltage or current intensity that occurs as the result of a particular sub-threshold stimulation pulse, and to determine a particular impedance value, an impedance evaluation unit, configured to determine at least one value based on ventricular volume, and/or a value based on minute ventilation, and a control unit connected to the stimulation unit and the cardiac rhythm detection unit, and is configured to control a delivery of a stimulation pulse via the stimulation unit such that the cardiac stimulator can deliver sub-threshold stimulation pulses for cardiac contraction modulation therapy.

Techniques are provided for monitoring thoracic fluid levels based on thoracic impedance (Z_T) and cardiogenic impedance (Z_C). In one example, the implantable device tracks the maximum time rate of change in cardiogenic impedance (i.e. max(dZ_C/dt)) to detect trends toward hypervolemic or hypovolemic states within the patient based on changes in heart contractility. The detection of these trends in combination with trends in thoracic impedance allows for a determination of whether the thoracic cavity of the patient is generally “too wet” or “too dry,” and thus allows for the titration of diuretics to avoid such extremes. In particular, a decrease in thoracic impedance (Z_T) in combination with a decrease in max (dZ_C/dt) is indicative of the thorax being “too wet” (i.e. a fluid overload). Conversely, an increase in thoracic impedance (Z_T) in combination with a decrease in max (dZ_C/dt) is indicative of the thorax being “too dry” (i.e. a fluid underload).

A method of facilitating therapeutic neuromodulation of a heart of a patient includes positioning an electrode in a pulmonary artery, positioning a sensor in vasculature, delivering via a stimulation system first and second electrical signals of a series of electrical signals to the electrode. The second electrical signal differs from the first electrical signal by a magnitude of a first parameter of a plurality of parameters. The method includes determining via the sensor, sensor data indicative of one or more heart activity properties in response to the delivery of the series of electrical signals, and delivering a therapeutic neuromodulation signal to the pulmonary artery using selected electrical parameters. The selected electrical parameters include a selected magnitude of the first parameter. The selected magnitude of the first parameter is based at least partially on the sensor data. The therapeutic neuromodulation signal increases heart contractility.

The invention discloses a distributed-type cardiovascular system simulation model. The distributed-type cardiovascular system simulation model is characterized by comprising a cardiac four-cavity sub-model, a pulmonary circulation sub-model, a blood vessel network sub-model, a reflection control sub-model and a vein collapse sub-model, the cardiac cavity sub-model is provided with a left ventricle connected with a left atrium and a right ventricle connected with a right atrium, the left ventricle and the right ventricle drive systemic circulation and pulmonary circulation, the blood vessel network sub-model comprises an arterial system, a peripheral circulation system and a venous system which are connected sequentially, an input end of the arterial system is connected with an output end of the left ventricle, an output end of the venous system is connected with an input end of the right ventricle, the vein collapse sub-model is connected with another input end of the venous system, an output end of the arterial system is connected with the reflection control sub-model through a carotid artery, and the reflection control sub-model controls blood pressure fluctuation of a model system through heart rate and heart contractility effectors arranged on the cardiac four-cavity model and arterial resistance, venous volume and vascular tone effectors arranged in the blood vessel network model.

At least one embodiment of the invention relates to a cardiac stimulator comprising at least one stimulation unit to deliver subthreshold stimulation pulses for a cardiac contractility modulation therapy via at least two stimulation electrode poles, and at least one sensing unit to detect cardiac electrical or mechanical actions. The at least one sensing unit detects signals characteristic of cardiac action and comprises, or is connected to, an evaluation unit that evaluates signals detected by the sensing unit and supplies a corresponding evaluation result signal. The cardiac stimulator further comprises a therapy control unit to control a respective cardiac contractility modulation therapy depending on a respective evaluation result signal. A respective cardiac contractility modulation therapy is activated/deactivated depending on a stimulation success/failure of a suprathreshold stimulation, and/or therapy parameters of a respective cardiac contractility modulation therapy are selected and/or adjusted depending on the respective evaluation result signal.

The invention provides a health care cold noodle containing Sauropus rostratus Miq powder and its production method. The health care cold noodle is made from 65-75 of flour, 8-10 of Sauropus rostratus Miq, 0.7-1.2 of tea polyphenols, 0.8-1.3 of sodium citrate, 1-1.5 of a peanut shell aqueous extract, 1-1.3 of carrageenan, 1.5-2.5 of Salvia Miltiorrhiza, 1.5-2.5 of Fructus Aurantii Immaturus, 1-1.5 of Polygonatum, 1-1.2 of lucid ganoderma, 0.6-1 of Prunus humilis Bunge leaf, 4-6 of hawthorn nuclear powder, 2-4 of pineapples, 2-3 of white sugar, 2-3 of table salt, and a proper amount of edible oil. The cold noodle produced in the invention changes the defects of unique taste and simple structural composition of traditional cold noodles. The Sauropus rostratus Miq powder added in the main materials not only improves the flavor, but also can clear away lung heat. The Salvia Miltiorrhiza added in the auxiliary materials can strengthen cardiac contractility, improve heart functions, increase myocardial blood flow, expand peripheral vessels, and lower blood pressure. The lucid ganoderma has an inhibitory effect on the nervous system, and has blood pressure lowering and heart contractility strengthening effects on the circulatory system. The Fructus Aurantii Immaturus, Polygonatum and the like all have certain blood pressure lowering efficacy. Long-term eating of the product provided in the invention is beneficial to the body health.

Bioengineering the regenerative heart or other body organ in need of greater muscle mass or improved blood perfusion provides a novel treatment for organ weakness or failure. In the case of cardiac failure treatment, on May 14, 2002, a 55-year-old man suffering ischemic myocardial infarction received 25 injections carrying 465 million cGMP-produced pure myoblasts into his myocardium after coronary artery bypass grafting. Three myogenesis mechanisms were elucidated with 17 human/porcine xenografts using cyclosporine as immunosuppressant. Some myoblasts developed to become cardiomyocytes. Others transferred their nuclei into host cardiomyocytes through natural cell fusion. As yet others formed skeletal myofibers with satellite cells. De novo production of contractile filaments augmented heart contractility. Human myoblasts transduced with VEGF165 gene produced six times more capillaries in porcine myocardium than placebo. Xenograft rejection was not observed for up to 20 weeks despite cyclosporine discontinuation at 6 weeks.

The invention relates to the field of medical instruments, in particular to a valve clamping device. The valve clamping device comprises a control rod, a first supporting piece, a clamping piece, at least one pair of folding pieces and at least one pair of closing pieces. The folding pieces are arranged on the two sides of the control rod respectively and correspond to the closing pieces. One end of the folding piece is rotationally connected with the control rod, the other end of the folding piece is movably connected with the first supporting piece, and the first supporting piece slides on the control rod; the closing piece is connected with the folding piece; and the clamping piece is arranged between the folding piece and the control rod. The opening and closing degree, namely the opening and closing degree of the valve, of the clamping device is adjusted by automatically adjusting the opening and closing angle through blood pressure driving; therefore, the effects of reducing blood regurgitation during cardiac contraction and reducing the resistance of blood passing through the valve during cardiac diastole are achieved.

The invention relates to the technical field of diagnosis of dilated cardiomyopathy (DCM), in particular to an automatic diagnosis system for human dilated cardiomyopathy. The system provided by the invention can realize the following diagnosis process: a heart image in a heart cycle is used as original data to be input, and a computer program can judge an end diastole image and an end systole image from the original data to segment a left ventricle and a right ventricle; and then heart parameters capable of reflecting the strain information of the left ventricle, the right ventricle and the ventricular muscle wall are calculated. After heart parameters are obtained, features of the heart parameters are input into a classifier, and DCM patients and non-DCM patients can be distinguished. The end-to-end full-automatic DCM diagnosis is realized, and compared with manual or semi-automatic diagnosis, the end-to-end full-automatic DCM diagnosis method has a good application prospect.

The invention relates to the technical field of medical instruments, and concretely relates to an auxiliary device for an aorta heart pump. The device comprises a combined bag, a combined catheter, an in-vitro pump and a controller, the combined bag comprises an inner bag, a middle bag and an outer bag which are sequentially connected in series, the combined catheter comprises an inner bag tube, a middle bag tube and an outer bag tube which are arranged in parallel, and the controller is connected with the in-vitro pump, and is used for controlling the in-vitro pump to inflate through the inner bag tube, the middle bag tube and the outer bag tube in sequence during diastole so as to enable the combined bag to expand from the far end to the near end in sequence, and exhausting through the inner bag tube, the middle bag tube and the outer bag tube in sequence during cardiac contraction so as to enable the combined bag to contract from the far end to the near end in sequence. The combined bag and the combined catheter are adopted, the combined bag can easily achieve sequential expansion or contraction from the far end to the near end of the air bag, and therefore when the combined bag expands, the driving effect on driving blood in the aorta to the whole body for blood supply and perfusion is larger, and when the combined bag contracts, the suction effect on heart blood discharge is larger.